The register of patients with heavy bronchial asthma in the territory of Russia

2019: Creation of the register of patients with heavy bronchial asthma in the territory of the Russian Federation

On December 19, 2019 the Astrazeneka company reported that in 2018 the Russian Respiratory Society with assistance of Astrazeneka company initiated work of a 5-year research on creation of "The register of patients with heavy bronchial asthma in the territory of the Russian Federation", being on treatment/observation in out-patient and polyclinic, treatment and prevention facilities and clinics of a health care system of the Russian Federation.

Main objectives of the project are – systematization of information on the heavy bronchial asthma (BA), including the description and characteristics of the general population of patients, assessment of diagnostics and treatment of this group of persons, monitoring of activity of a disease and efficiency of the carried-out therapy for timely correction and development of the personalized approach to each patient.

This research is the observation and not intervention. Participation of the patient in a research does not affect character and volume of inspections and therapy in any way. Patients receive medical care according to requirements of the existing standards of therapy of this disease in the Russian Federation. The created database of the register completely anonymous, personal data of patients are known only to the attending physician.

For December, 2019 285 specialists from 57 regions of the Russian Federation take part in work of the register and more than 2,800 patients are registered. By 2023 it is going to include about 7000 patients. The register considers patients with hard cases and promotes creation of a full-fledged picture of a course of a disease at the population level in the Russian Federation.

The first data on results of the intermediate analysis were provided in 2019 on 2 large international congresses on respiratory medicine and attracted great interest among participants. The analysis of the first results showed that the most widespread age of a debut of a disease falls on 31-50 years, and its average duration – about 20 years. The most widespread associated diseases, according to the register, are allergic rhinitis and arterial hypertension. The received results showed that more than 90% of patients have an uncontrollable current of BA with a frequency of aggravations ≥ 2 for the last 12 months, from them about 80% with reduced function of external breath.

However it should be noted that not to all patients included in the register the assessment of biomarkers is carried out – the research of level of eosinophils in peripheral blood is executed of 2534 patients at 742 (29.3%), and the general immunoglobulin of serum of blood at 972 (38.4%) in spite of the fact that these indicators are leaders for carrying out feno-and endotypings and also at decision-making concerning purpose of targetny therapy.

In the analysis of therapy which is received by patients in the conditions of real clinical practice it was established that 8.5% of patients receive therapy by system glucocorticosteroids (SGKS) and only a small part – therapy by genetically engineered biological medicines (n=146 (5.8%)). 1.2

The quality and reliability entered to a data register is extremely important for receiving the relevant scientific information, and their further accumulation will allow to receive more exact picture on a disease in the territory of the Russian Federation, consider in Astrazenek.